Literature DB >> 18446607

PLGA microspheres for the delivery of a novel subunit TB vaccine.

Daniel J Kirby1, Ida Rosenkrands, Else M Agger, Peter Andersen, Allan G A Coombes, Yvonne Perrie.   

Abstract

Biodegradable poly(dl-lactide-co-glycolide) microspheres were prepared using a modified double emulsion solvent evaporation method for the delivery of the subunit tuberculosis vaccine (Ag85B-ESAT-6), a fusion protein of the immunodominant antigens 6-kDa early secretory antigenic target (ESAT-6) and antigen 85B (Ag85B). Addition of the cationic lipid dimethyl dioctadecylammonium bromide (DDA) and the immunostimulatory trehalose 6,6'-dibehenate (TDB), either separately or in combination, was investigated for the effect on particle size and distribution, antigen entrapment efficiency, in vitro release profiles and in vivo performance. Optimised formulation parameters yielded microspheres within the desired sub-10 microm range (1.50 +/- 0.13 microm), whilst exhibiting a high antigen entrapment efficiency (95 +/- 1.2%) and prolonged release profiles. Although the microsphere formulations induced a cell-mediated immune response and raised specific antibodies after immunisation, this was inferior to the levels achieved with liposomes composed of the same adjuvants (DDA-TDB), demonstrating that liposomes are more effective vaccine delivery systems compared with microspheres.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446607     DOI: 10.1080/10611860801900462

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  17 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 3.  Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines.

Authors:  Raymonde B Bekale; Su-Mari Du Plessis; Nai-Jen Hsu; Jyoti R Sharma; Samantha L Sampson; Muazzam Jacobs; Mervin Meyer; Gene D Morse; Admire Dube
Journal:  Pharm Res       Date:  2018-11-08       Impact factor: 4.200

4.  PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B.

Authors:  Shuai Shi; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-12-19       Impact factor: 4.200

5.  Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.

Authors:  Anirudh Gairola; Aaron Benjamin; Joshua D Weatherston; Jeffrey D Cirillo; Hung-Jen Wu
Journal:  Adv Ther (Weinh)       Date:  2022-03-09

Review 6.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

7.  Lactoferrin modulation of BCG-infected dendritic cell functions.

Authors:  Shen-An Hwang; Jeffrey K Actor
Journal:  Int Immunol       Date:  2009-08-19       Impact factor: 4.823

8.  Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy.

Authors:  Kyle E Broaders; Joel A Cohen; Tristan T Beaudette; Eric M Bachelder; Jean M J Fréchet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

Review 9.  Nanobead-based interventions for the treatment and prevention of tuberculosis.

Authors:  Gareth Griffiths; Bo Nyström; Suraj B Sable; Gopal K Khuller
Journal:  Nat Rev Microbiol       Date:  2010-10-12       Impact factor: 60.633

10.  A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice.

Authors:  Young Mee Yoon; Jamal S Lewis; Matthew R Carstens; Martha Campbell-Thompson; Clive H Wasserfall; Mark A Atkinson; Benjamin G Keselowsky
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.